TRT and Antidepressants: What Actually Interacts and What to Watch

TRT and antidepressants get prescribed to the same men all the time, and the interaction checkers say there’s nothing to report: no drug-drug interaction on file. The checkers are answering a narrow question, whether one drug changes the blood level of the other. Testosterone doesn’t.

The questions men bring me are wider than that. Will testosterone make me irritable on top of my sertraline? Is my sex drive gone because of the Lexapro or because of low T? Can I drop the antidepressant once my levels come up?

Four effects overlap when these drugs share a patient: mood, sexual function, blood counts, and blood pressure. Every one of them shows up on a lab result or a blood-pressure cuff. I’m a board-certified psychiatrist who prescribes both, so these are calls I make in clinic.

Short Answer

There’s no documented pharmacokinetic interaction between testosterone and SSRIs, SNRIs, bupropion, or mirtazapine. In the placebo-controlled trials that added testosterone to serotonergic antidepressants, the combination was well tolerated (PMID 21707327). The management sits in four places. Mood needs watching in the first weeks, especially with any bipolar history. Sexual side effects need a differential, because SSRIs and low testosterone impair sex in similar-looking ways. Hematocrit needs scheduled checks. Blood pressure does too, especially with venlafaxine. Testosterone isn’t FDA-approved for depression, but in men with a measured deficiency, correcting it can improve mood, sometimes substantially.

Will TRT Make You Irritable on an Antidepressant?

Men who start testosterone while on sertraline often notice they’re snappier by week three, and they want to know which drug did it.

At replacement doses, the controlled data doesn’t point at testosterone. Across 27 randomized trials, men on testosterone were no more likely to stop treatment over side effects than men on placebo, with an odds ratio of 0.79 (PMID 30427999). Physiologic dosing, confirmed with labs, doesn’t produce a consistent irritability signal.

The rage literature comes from doses nobody should be prescribed. When healthy men got 600 mg of testosterone cypionate weekly for six weeks, roughly six times a replacement dose, 12% developed mild hypomania and 4% became markedly hypomanic (PMID 10665615). Another trial gave a single 1,000 mg dose to men with normal testosterone and recorded a small rise in anger-hostility scores with no change in aggressive behavior (PMID 15181066). That’s the anabolic-steroid literature, at doses far above anything I prescribe.

When irritability does show up in the first weeks, the workup goes in order. Check the level. A total testosterone above the reference range makes the dose the first suspect, and lowering it usually settles things. A mid-range level sends me looking at the more common culprits: antidepressant-related activation, poor sleep, alcohol, a bad month at work. Testosterone and anger have a more complicated relationship than the stereotype suggests, and I’ve written about it separately.

One caution holds at any dose. Case reports describe manic episodes emerging on testosterone in men with bipolar disorder or a prior hypomanic episode (PMID 10360145; PMID 30076163). The literature is thin, and I act on it anyway. The cost of missing this is a manic episode, and screening for it costs one intake question.

Sexual Side Effects: Which Drug Is Doing It?

Antidepressants and low testosterone both flatten sex drive, and they get mistaken for each other in both directions.

In a prospective study of 1,022 patients on antidepressants, 59% developed treatment-emergent sexual dysfunction, and the rates for several SSRIs and venlafaxine ran between 58% and 73% (PMID 11229449). Low testosterone causes low desire and weaker erections on its own, through a different mechanism, on a different timeline.

Timing does most of the diagnostic work. Sexual dysfunction that appeared within weeks of starting or raising an antidepressant, in a man whose morning testosterone is normal, is a medication effect. Trouble that predates the prescription, alongside fatigue and a morning total testosterone under roughly 300 ng/dL, points at the hormone.

Can testosterone reverse antidepressant-related sexual dysfunction? In one placebo-controlled trial it did, for a specific group. Depressed men on serotonergic antidepressants, screened at 350 ng/dL or below, improved by 15.8 points on the International Index of Erectile Function with testosterone gel while the placebo group slightly declined (PMID 21707327). The same cohort showed no advantage over placebo on depression scores (PMID 20520285). My read: testosterone earned a role for sexual function in men who measure low. In a man whose testosterone is normal, using it for antidepressant sexual side effects is off-label, and the trial evidence runs out. The cleaner fix there is usually on the antidepressant side, often a switch to bupropion, which is among the antidepressants least likely to impair sexual function.

Sexual dysfunction that persists after stopping an SSRI is its own entity with its own literature. I’ve covered post-SSRI sexual dysfunction separately.

Can TRT Help Depression Itself?

Pooled across 27 randomized trials, testosterone beat placebo on depressive symptoms with a small average effect, a Hedges g of 0.21, that grew with dose (PMID 30427999). The augmentation trials split: a small trial in refractory depression was positive on two of three scales (PMID 12505808), a second was underpowered and missed significance (PMID 16282843), and the largest was negative (PMID 20520285).

Averages hide the split that matters clinically. The men who respond, in my experience and disproportionately in the trial subgroups, are the ones who measure low. In a man with a total testosterone near 200 ng/dL, fatigue, no libido, and a mood that never fully lifted on two antidepressants, correcting the deficiency can change the picture substantially. In a man with normal levels, the trial record gives testosterone no antidepressant role, and FDA approval covers hypogonadism only.

I treat it as a candidacy question. Depressive symptoms plus a verified low level make TRT worth discussing as an addition to the antidepressant, and the antidepressant stays. The full case, trials, doses, and where augmentation fits, lives in my guide to testosterone augmentation for depression.

TRT and Antidepressants, Drug by Drug

Sertraline, Escitalopram, and the Other SSRIs

There’s no pharmacokinetic interaction. The overlap is the sexual-function confound above and early activation. If the SSRI is new, I give it 2 to 4 weeks before adding a second variable, because starting both drugs the same week turns side-effect attribution into guesswork.

Bupropion

No documented interaction. Bupropion is the antidepressant least likely to cause sexual dysfunction, which is why bupropion plus TRT is a deliberate pairing in men whose depression comes with low energy and low libido.

Venlafaxine

Venlafaxine is the exception. It raises blood pressure dose-dependently, and sustained hypertension became statistically and clinically significant above 300 mg per day in a pooled analysis of 3,744 patients (PMID 9818630). Testosterone’s current FDA label carries its own blood-pressure warning. Stacked, the two justify a cuff at every visit and a home log at higher venlafaxine doses.

Blood Counts, Bleeding, and Blood Pressure

SSRIs deplete platelet serotonin and impair aggregation, which roughly doubles the odds of upper-GI bleeding. The absolute risk stays low until NSAIDs, anticoagulants, or antiplatelets join the mix (PMID 21190637).

Testosterone does the opposite. It raises hematocrit, and the route matters: intramuscular injections raised hematocrit about 4 points in a network meta-analysis versus 1.4 for patches (PMID 34445892), and a matched cohort found 4.4 points for injections against a slight decline for nasal gel (PMID 37068153). Nobody has studied whether an SSRI’s platelet effect offsets any of that, so I treat them as two separate risks, each monitored on its own schedule, and I lean transdermal when hematocrit runs high. High hematocrit on TRT has a full management protocol, which I’ve covered in detail.

The big cardiovascular picture is steadier than the old boxed warning implied. TRAVERSE followed 5,246 men for a mean of 33 months and found no excess in major cardiac events (hazard ratio 0.96), alongside higher rates of atrial fibrillation and pulmonary embolism in the testosterone arm (PMID 37326322). The FDA removed the cardiovascular boxed warning in February 2025 and added the blood-pressure warning in the same revision.

Who Needs Extra Caution Before Combining

The list is short, and most men aren’t on it. Men with bipolar disorder or past hypomania can still be candidates; the mood gets monitored deliberately, by someone who knows what activation looks like. A hematocrit already in the low 50s needs addressing before testosterone starts, because TRT will push it higher (PMID 29562364). An unresolved prostate question, a nodule or a rising PSA, pauses TRT until urology clears it. A history of unprovoked clots deserves a serious conversation about route and monitoring before the first dose.

The label context, dated because it’s moving: since February 28, 2025, testosterone’s class label has no cardiovascular boxed warning, carries a blood-pressure warning, and limits approval to low testosterone with an associated medical condition. In June 2026, FDA and HHS requested further easing, including removal of the age-related limitation (HHS, June 18, 2026). That request wasn’t final as of late July 2026. The label movement is about hypogonadism categories. Depression stays off-label either way.

How I Run the Combination

Baseline first: a morning total testosterone (repeated when the number is borderline), hematocrit, PSA where age-appropriate, and a blood pressure. Mood gets a named baseline too, because “better” needs a reference point.

Then set the cadence. Recheck the testosterone level at 3 months to confirm it landed in the mid-normal range, because overshooting is the most common cause of trouble. Recheck hematocrit at 3, 6, and 12 months, then yearly, following the Endocrine Society and AUA frameworks (PMID 29562364; PMID 29601923). Check blood pressure at every visit when venlafaxine is aboard, and review mood at every contact for the first two months and after any dose change on either side.

When something goes sideways early, I adjust the newest variable first. If TRT was added last, TRT is what I adjust first: level, dose, interval, route. Raising the antidepressant to cover testosterone-related activation targets the wrong drug. In a man with any bipolar history, activation calls for a full psychiatric reassessment. Pushing through it with a higher dose can tip him into mania.

This monitoring is standard in my practice. The full structure is on my TRT therapy page.

Frequently Asked Questions

Can I start TRT while taking Zoloft or Lexapro?

Yes, with monitoring. There’s no documented pharmacokinetic interaction, and controlled trials that added testosterone to serotonergic antidepressants tolerated it well. The practical rule is one new variable at a time: if the antidepressant is new, let it settle for a few weeks before starting testosterone, so any side effect can be attributed to the right drug.

Will TRT let me stop my antidepressant?

Plan on keeping the antidepressant. The largest trial that added testosterone in depressed men showed no advantage over placebo on depression scores, and testosterone has no FDA approval for depression. When mood improves substantially on the combination, any antidepressant taper is its own supervised decision, made slowly and separately from the TRT question.

Does TRT interact with Wellbutrin (bupropion)?

No interaction is documented. The pairing is often deliberate, because bupropion is the antidepressant least likely to cause sexual dysfunction, and men pursuing TRT usually care about preserving sexual function. The same monitoring schedule applies: testosterone level, hematocrit, and blood pressure on cadence.

How fast does mood change after starting TRT?

When testosterone was low to begin with, energy and mood typically shift over 3 to 6 weeks, and sexual function over 3 to 12 weeks. Improvement in the first few days is likelier to be expectation than pharmacology. I track mood at every visit for the first two months, so the trajectory gets measured from the start.

Should my testosterone be checked before starting an antidepressant?

In men with low libido, fatigue, and a flat mood, yes. A morning total testosterone belongs in the baseline workup, because low testosterone and depression overlap enough that treating one while missing the other leaves men on the wrong monotherapy for years.

Disclaimer: This article is for educational purposes only and is not medical advice. Starting, combining, or stopping testosterone or antidepressant therapy requires personalized diagnosis, lab monitoring, and consultation with a licensed provider. Monthly plans cover Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are not included and are paid separately by the patient. If you’re having thoughts of suicide or are in a mental health crisis, call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency department.

---

References

1. Amiaz R, et al. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants. J Sex Marital Ther. 2011. PMID: 21707327

2. Walther A, et al. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019. PMID: 30427999

3. Pope HG Jr, et al. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000. PMID: 10665615

4. O’Connor DB, et al. Effects of testosterone on mood, aggression, and sexual behavior in young men. J Clin Endocrinol Metab. 2004. PMID: 15181066

5. Weiss EL, et al. Testosterone-patch-induced psychotic mania. Am J Psychiatry. 1999. PMID: 10360145

6. Elboga G, et al. Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement. BMJ Case Rep. 2018. PMID: 30076163

7. Montejo AL, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001. PMID: 11229449

8. Pope HG Jr, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010. PMID: 20520285

9. Pope HG Jr, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003. PMID: 12505808

10. Seidman SN, et al. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men. J Clin Psychopharmacol. 2005. PMID: 16282843

11. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998. PMID: 9818630

12. Andrade C, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010. PMID: 21190637

13. Nackeeran S, et al. The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network meta-analysis of randomized trials. J Urol. 2022. PMID: 34445892

14. Reddy R, et al. Prevalence of secondary erythrocytosis in men receiving testosterone therapy: a matched-cohort analysis of intranasal gel, injections, and pellets. Can Urol Assoc J. 2023. PMID: 37068153

15. Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023. PMID: 37326322

16. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. PMID: 29562364

17. Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018. PMID: 29601923

18. FDA. FDA issues class-wide labeling changes for testosterone products. Drug Safety Communication. February 28, 2025. fda.gov

19. U.S. Department of Health and Human Services. HHS and FDA request updates to testosterone therapy product labels. June 18, 2026. hhs.gov